TAK-637. Takeda.
Abbott and Takeda are developing TAK-637, an orally active NK1 antagonist, for the potential treatment of urinary incontinence, depression, irritable bowel syndrome and pollakiuria. By November 1999, it was in phase II trials in Europe and phase I in Japan and the US for urinary incontinence [348496], [350686]. By October 2000, phase II trials had been initiated in the US for urinary incontinence, depression and IBS [381167], [386950], [419868], and in May 2001, these were scheduled to finish in 2002 [412024].
Furness
J B
JB
Department of Anatomy and Cell Biology, University of Melbourne, Victoria, Australia. j.furness@unimelb.edu.au
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D003863:Depression / Q000188:drug therapy*; D006801:Humans; D009287:Naphthyridines / Q000494:pharmacology / Q000627:therapeutic use*; D064729:Neurokinin-1 Receptor Antagonists; D013329:Structure-Activity Relationship; D014549:Urinary Incontinence / Q000188:drug therapy*
D009287:Naphthyridines; D064729:Neurokinin-1 Receptor Antagonists; C403052:TAK 637